Search

TARGETING THE JAK-STAT PATHWAY IN MALIGNANT AND NON-MALIGNANT CELLS IN MYELOPROLIFERATIVE NEOPLASMS

Jun 14 2013

Myeloproliferative neoplasms (MPN) are clonal blood disorders characterized by excessive production of mature blood cells. Patients present with large spleens, systemic symptoms, and high levels of circulating inflammatory cytokines.

Novel basis for chemoresistance in AML: DNMT3A R882 mutations promote chemoresistance and residual disease through impaired DNA damage sensing

Jun 12 2015 Posted in Press releases

Although most acute myeloid leukemia (AML) patients initially respond to chemotherapy, the majority subsequently relapses and succumbs to refractory disease. Residual leukemic cells that survived chemotherapy may persist over time and later cause the disease to come back.

First randomized evidence for kinase inhibitor activity in acute myeloid leukemia

Jun 12 2015 Posted in Press releases

Despite the success of tyrosine kinase inhibitors in some forms of leukemias such as chronic myeloid leukemia and acute lymphoblastic leukemia, until now a kinase inhibitor had yet to demonstrate activity in acute myeloid leukemia (AML).

“Science is all about synergy” - Francesca Vinchi, woman in hematology/EHA volunteer

Mar 15 2019

This Women’s History Month, we are putting the spotlight on women in hematology. One of them is Francesca Vinchi, also an EHA Volunteer.

Do generics of imatinib jeopardize patient safety for the sake of saving money? An experience in Turkish patients.

Jun 13 2014 Posted in Press releases

The high cost of tyrosine kinase inhibitors developed for chronic myeloid leukemia is a major concern for the health care payers, especially in countries with restricted resources.

Gdf -11 a new target to improve anemia in thalassemia.

Jun 13 2014 Posted in Press releases

β-thalassemias are characterized by ineffective red blood cell (RBC) production, leading to anemia, iron overload, and organ failure. As current treatment options for β-thalassemia are limited, there is a clear unmet need for alternative therapies.

Chairs and Members

Chair (2017-present)Oliver A. Cornely—University Hospital Cologne, Cologne (Germany)

Co-chair (2023-present)Livio Pagano—Fondazione Policlinico A.

SWG Educational Activities

SWG meeting, EHA2023 CongressGuidelines SessionSession title‘The European Guidelines on Diagnosis and Management of Neutropenia in Adults and Children.